Fovinaciclib一线治疗晚期乳腺癌的随机临床试验
这项双盲3期随机试验在中国63个中心纳入417例激素受体阳性、ERBB2阴性晚期乳腺癌患者,比较fovinaciclib或安慰剂联合芳香化酶抑制剂一线治疗。主要终点BICR评估的PFS在fovinaciclib组显著延长(未达到 vs 20.2个月;HR 0.55;95%CI 0.38-0.77;
要点
- fovinaciclib联合芳香化酶抑制剂一线治疗显著延长BICR评估的PFS(HR 0.55)。
- 最常见治疗中出现的不良事件为血液学毒性,因不良事件停药率仅1.4%。
- 总生存数据尚不成熟,仅40例事件(9.6%)。
核心结论
- 在激素受体阳性、ERBB2阴性晚期乳腺癌一线治疗中,fovinaciclib联合芳香化酶抑制剂较安慰剂联合芳香化酶抑制剂显著延长BICR评估的PFS,且安全可控、生活质量不受影响。
研究设计与样本
- 双盲、3期随机临床试验,2022年3月2日至2023年6月28日从中国63个中心入组417例成年女性激素受体阳性、ERBB2阴性晚期乳腺癌患者,既往未接受晚期疾病全身治疗。
- 患者按1:1随机接受fovinaciclib 200 mg(口服,每日一次,第1-21天)或安慰剂,联合来曲唑2.5 mg或阿那曲唑1 mg(口服,每日一次,第1-28天),28天为一周期;绝经前或围绝经期患者另接受戈舍瑞林3.6 mg(皮下注射,第1天)。
- 主要终点为BICR评估的PFS;次要终点包括其他疗效终点和安全性;探索性终点包括OS和生活质量。
- 数据截止日期为2024年6月25日;预设中期分析时中位(范围)随访16.6(0.3-27.8)个月。
主要发现
- fovinaciclib组208例,安慰剂组209例;中位(范围)年龄57.0(32-84)岁。
- 大多数患者亚组中观察到一致的PFS获益;fovinaciclib在其他次要疗效终点上也更优。
- OS数据不成熟,仅40例事件(9.6%)。
- 最常见治疗中出现的不良事件为血液学毒性,未导致严重不良事件或研究药物停药;因治疗中出现的不良事件停药率两组均为1.4%(fovinaciclib组3/208,安慰剂组3/209)。
临床怎么用
- 对于激素受体阳性、ERBB2阴性晚期乳腺癌且无晚期疾病全身治疗史的患者,可考虑fovinaciclib联合芳香化酶抑制剂作为一线治疗选择。
- 治疗期间需关注血液学毒性,但因不良事件停药率低,安全性总体可控。
局限性
- OS数据尚不成熟,仅有40例事件(9.6%),需更长期随访。
- 研究仅在中国63个中心进行,外推性需考虑人群差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Approximately 70% of patients with breast cancer (BC) have hormone receptor-positive, human epidermal growth factor receptor 2 (ERBB2; formerly HER2)-negative disease. OBJECTIVE: To evaluate the efficacy and safety of fovinaciclib plus an aromatase inhibitor as first-line treatment for hormone receptor-positive, ERBB2-negative advanced BC. DESIGN, SETTING, AND PARTICIPANTS: This double-blind, phase 3 randomized clinical trial enrolled patients from March 2, 2022, to June 28, 2023, from 63 centers in China. Eligible patients were adult women with hormone receptor-positive, ERBB2-negative advanced BC and no history of systemic therapy for advanced disease. The data cutoff date was June 25, 2024. Data were analyzed from September to October 2024. INTERVENTION: Patients were randomized (1:1) to receive fovinaciclib, 200 mg (orally once daily on days 1 to 21), or placebo plus letrozole, 2.5 mg, or anastrozole, 1 mg (orally once daily on days 1 to 28), in 28-day cycles. Premenopausal or perimenopausal patients also received goserelin, 3.6 mg (subcutaneously on day 1). MAIN OUTCOMES AND MEASURES: The primary end point was progression-free survival (PFS) per blinded independent central review (BICR). Secondary end points included other efficacy end points and safety. Exploratory end points included overall survival (OS) and quality of life. RESULTS: Of 417 randomized female patients, the median (range) age was 57.0 (32-84) years. A total of 208 were randomized to the fovinaciclib arm and 209 to the placebo arm. At prespecified interim analysis (median [range] follow-up, 16.6 [0.3-27.8] months), a significantly prolonged median PFS was observed with fovinaciclib compared with placebo (not reached vs 20.2 months [95% CI, 16.4 months to not evaluable]; hazard ratio, 0.55; 95% CI, 0.38-0.77; 1-sided P < .001) per BICR assessments. Consistent PFS benefit was observed in most patient subgroups. Fovinaciclib was also favored across secondary efficacy end points. OS data were immature, with only 40 events (9.6%). The most common treatment-emergent adverse events were hematologic toxic effects, none of which led to serious adverse events or study drug discontinuation. Incidence of discontinuation due to treatment-emergent adverse events was only 1.4% in both arms (3 of 208 receiving fovinaciclib and 3 of 209 receiving placebo). Longitudinal changes in global health status, function domains, and symptom domains of European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 were similar between the 2 arms. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, adding fovinaciclib to first-line aromatase inhibitor conferred significant and clinically meaningful PFS benefit and consistent improvements in other efficacy outcomes, along with manageable safety and unaffected quality of life. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05439499.
引用
- Yuan P, Liu Y, Li W, et al. Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2026. PMID: 42224659. doi:10.1001/jamaoncol.2026.1938
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。